Galectin Therapeutics (GALT) said Friday its trial evaluating belapectin in cirrhotic portal hypertension patients showed a 48.9% reduction in varices in the per-protocol population for the 2 mg/kg dose group.
In the intent-to-treat population, while the incidence of varices showed a 43.2% reduction, "the composite endpoint did not reach statistical significance," the company said.
The safety profile of belapectin remained favorable, the company said.
Galectin Therapeutics' shares were nearly 30% lower in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.